Exane Derivatives’s MaxCyte MXCT Stock Holding History

Exane Derivatives’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2.33K	Buy	+502	New	+$2.47K	﹤0.01%	425
2022 Q1	–	Sell	-27,307	Closed	-$278K	–	1065
2021 Q4	$278K	Sell	27,307 -6,365	-19%	-$68.4K	0.07%	274
2021 Q3	$411K	Buy	+33,672	New	+$508K	0.1%	220

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Exane Derivatives's MXCT Position: Q2 2022 in Review

Exane Derivatives opened a new position in MaxCyte (MXCT) in Q2 2022: 502 shares worth $2.33K. The stake represents ﹤0.01% of the portfolio and ranks #425 among its holdings. This is a return to the name: Exane Derivatives previously reported a position in MXCT as recently as Q4 2021.

Exane Derivatives first reported a position in MXCT in Q3 2021 and has held it in 3 quarters since. The position peaked at $411K in Q3 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

Exane Derivatives held 502 shares of MaxCyte worth $2.33K as of Q2 2022.
MaxCyte was a new Exane Derivatives position in Q2 2022.
MaxCyte made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #425 holding.
Exane Derivatives first reported a position in MaxCyte in Q3 2021 and has held it in 3 quarters since.
Exane Derivatives's MaxCyte position peaked at $411K in Q3 2021.
102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.